speb/financial-data huggingface dataset:
CURA.TO cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: 3333000.00
CURA.TO balance_sheet (annual, 2021-12-31) — Gross Accounts Receivable: 60065000.00
CURA.TO balance_sheet (annual, 2021-12-31) — Inventories Adjustments Allowances: -2110000.00
CURA.TO cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 240569000.00
CURA.TO cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 240569000.00
CURA.TO balance_sheet (annual, 2021-12-31) — Non Current Prepaid Assets: 0.00
CURA.TO cash_flow (annual, 2021-12-31) — Other Cash Adjustment Outside Changein Cash: 0.00
CURA.TO balance_sheet (annual, 2021-12-31) — Other Inventories: 211911000.00
CURA.TO balance_sheet (annual, 2021-12-31) — Prepaid Assets: 35667000.00
CURA.TO balance_sheet (annual, 2021-12-31) — Treasury Stock: 5208000.00
CURA.TO income_statement (annual, 2022-12-31) — +Operating Expense: 561431000.00
CURA.TO income_statement (annual, 2022-12-31) — +Total Revenue: 1275420000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Accounts Payable: 80789000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 44423000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -167859000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 2163061000.00
CURA.TO cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 82615000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 180452000.00
CURA.TO income_statement (annual, 2022-12-31) — Basic Average Shares: 237053147.00
CURA.TO income_statement (annual, 2022-12-31) — Basic EPS: -1.56
CURA.TO cash_flow (annual, 2022-12-31) — Beginning Cash Position: 299329000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 442749000.00
CURA.TO cash_flow (annual, 2022-12-31) — Capital Expenditure: -134643000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 306059000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Capital Stock: 0.00
CURA.TO balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 163177000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 163177000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 41813000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -210184000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 67722000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash From Discontinued Financing Activities: -19000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash From Discontinued Investing Activities: -9696000.00
CURA.TO cash_flow (annual, 2022-12-31) — Cash From Discontinued Operating Activities: -21319000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Account Payable: 50094000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 56403000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Income Tax Payable: 7814000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Inventory: -16103000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Other Current Assets: 4267000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Other Current Liabilities: -5309000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 2872000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Payable: 57908000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 114311000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -10905000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Receivables: -20220000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Tax Payable: 7814000.00
CURA.TO cash_flow (annual, 2022-12-31) — Change In Working Capital: 66041000.00
CURA.TO cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -3329000.00
CURA.TO cash_flow (annual, 2022-12-31) — Changes In Cash: -131683000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Common Stock: 0.00
CURA.TO balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1279705000.00
CURA.TO cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
CURA.TO balance_sheet (annual, 2022-12-31) — Construction In Progress: 81032000.00
CURA.TO income_statement (annual, 2022-12-31) — Cost Of Revenue: 649001000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 32121000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Assets: 652425000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 25341000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Debt: 51882000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 77223000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Deferred Liabilities: 25122000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Deferred Revenue: 676000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Current Liabilities: 496868000.00
CURA.TO cash_flow (annual, 2022-12-31) — Deferred Income Tax: -15121000.00
CURA.TO cash_flow (annual, 2022-12-31) — Deferred Tax: -15121000.00
CURA.TO cash_flow (annual, 2022-12-31) — Depreciation: 165641000.00
CURA.TO cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 165641000.00
CURA.TO income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 113534000.00
CURA.TO cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 165641000.00
CURA.TO income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 113534000.00
CURA.TO income_statement (annual, 2022-12-31) — Diluted Average Shares: 237053147.00
CURA.TO income_statement (annual, 2022-12-31) — Diluted EPS: -1.56
CURA.TO income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: -370099000.00
CURA.TO cash_flow (annual, 2022-12-31) — Dividends Received Cfi: 468000.00
CURA.TO income_statement (annual, 2022-12-31) — EBIT: 2354000.00
CURA.TO income_statement (annual, 2022-12-31) — EBITDA: 167995000.00
CURA.TO cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -4469000.00
CURA.TO cash_flow (annual, 2022-12-31) — End Cash Position: 163177000.00
CURA.TO cash_flow (annual, 2022-12-31) — Financing Cash Flow: 41794000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Finished Goods: 68158000.00
CURA.TO cash_flow (annual, 2022-12-31) — Free Cash Flow: -88240000.00
CURA.TO cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -21952000.00
CURA.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: -548000.00
CURA.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 21952000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -18594000.00
CURA.TO income_statement (annual, 2022-12-31) — General And Administrative Expense: 408150000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Goodwill: 625129000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 1838432000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 44423000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Gross PPE: 1038446000.00
CURA.TO income_statement (annual, 2022-12-31) — Gross Profit: 626419000.00
CURA.TO income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 82615000.00
CURA.TO cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 155954000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Income Tax Payable: 149569000.00
CURA.TO income_statement (annual, 2022-12-31) — Interest Expense: 88842000.00
CURA.TO income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 88842000.00
CURA.TO income_statement (annual, 2022-12-31) — Interest Income: 136000.00
CURA.TO income_statement (annual, 2022-12-31) — Interest Income Non Operating: 136000.00
CURA.TO cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 78828000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Interest Payable: 3897000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Inventories Adjustments Allowances: -2983000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Inventory: 234782000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Invested Capital: 1902375000.00
CURA.TO cash_flow (annual, 2022-12-31) — Investing Cash Flow: -219880000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Investments And Advances: 2797000.00
CURA.TO cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
CURA.TO cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
CURA.TO balance_sheet (annual, 2022-12-31) — Land And Improvements: 6576000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 280718000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Long Term Debt: 570788000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 851506000.00
CURA.TO cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
CURA.TO cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -8873000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 185284000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Minority Interest: 121113000.00
CURA.TO income_statement (annual, 2022-12-31) — Minority Interests: 6833000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -78324000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
CURA.TO balance_sheet (annual, 2022-12-31) — Net Debt: 459493000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income: -370099000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -370099000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -265310000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income Discontinuous Operations: -111622000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -370099000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -258477000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: -265310000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -376932000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: 0.00
CURA.TO income_statement (annual, 2022-12-31) — Net Interest Income: -88706000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -8873000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -8873000.00
CURA.TO income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -88706000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 51498000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 2315000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Net PPE: 870587000.00
CURA.TO cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -134643000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -558727000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Accounts Receivable: 33296000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 1564000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 345828000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 1564000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 308974000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Non Current Note Receivables: 0.00
CURA.TO income_statement (annual, 2022-12-31) — Normalized EBITDA: 229001000.00
CURA.TO income_statement (annual, 2022-12-31) — Normalized Income: -210282260.00
CURA.TO balance_sheet (annual, 2022-12-31) — Notes Receivable: 0.00
CURA.TO cash_flow (annual, 2022-12-31) — Operating Cash Flow: 46403000.00
CURA.TO cash_flow (annual, 2022-12-31) — Operating Gains Losses: -21609000.00
CURA.TO income_statement (annual, 2022-12-31) — Operating Income: 64988000.00
CURA.TO income_statement (annual, 2022-12-31) — Operating Revenue: 1275420000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 239163609.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Current Assets: 28835000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 51882000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 61530000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -18594000.00
CURA.TO income_statement (annual, 2022-12-31) — Other Gand A: 118883000.00
CURA.TO income_statement (annual, 2022-12-31) — Other Income Expense: -62770000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 1213303000.00
CURA.TO cash_flow (annual, 2022-12-31) — Other Non Cash Items: 24330000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 15459000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Non Current Liabilities: 225024000.00
CURA.TO income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -1764000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Payable: 60829000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Properties: 322805000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Other Receivables: 4798000.00
CURA.TO income_statement (annual, 2022-12-31) — Other Special Charges: -205000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Payables: 300872000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 332993000.00
CURA.TO income_statement (annual, 2022-12-31) — Pretax Income: -86488000.00
CURA.TO cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: -812000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Properties: 0.00
CURA.TO cash_flow (annual, 2022-12-31) — Provisionand Write Offof Assets: 3118000.00
CURA.TO cash_flow (annual, 2022-12-31) — Purchase Of Business: -119205000.00
CURA.TO cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: 0.00
CURA.TO cash_flow (annual, 2022-12-31) — Purchase Of PPE: -134643000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Raw Materials: 64574000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Receivables: 45179000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Receivables Adjustments Allowances: -4042000.00
CURA.TO income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 596894000.00
CURA.TO income_statement (annual, 2022-12-31) — Reconciled Depreciation: 165641000.00
CURA.TO income_statement (annual, 2022-12-31) — Rent And Landing Fees: 49824000.00
CURA.TO income_statement (annual, 2022-12-31) — Rent Expense Supplemental: 49824000.00
CURA.TO cash_flow (annual, 2022-12-31) — Repayment Of Debt: -8873000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Retained Earnings: -859554000.00
CURA.TO income_statement (annual, 2022-12-31) — Salaries And Wages: 239443000.00
CURA.TO cash_flow (annual, 2022-12-31) — Sale Of Business: 40881000.00
CURA.TO income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 39747000.00
CURA.TO income_statement (annual, 2022-12-31) — Selling General And Administration: 447897000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Share Issued: 239163609.00
CURA.TO income_statement (annual, 2022-12-31) — Special Income Charges: -82958000.00
CURA.TO cash_flow (annual, 2022-12-31) — Stock Based Compensation: 28017000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Stockholders Equity: 1279705000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Tangible Book Value: -558727000.00
CURA.TO income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -12811260.00
CURA.TO income_statement (annual, 2022-12-31) — Tax Provision: 178822000.00
CURA.TO income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (annual, 2022-12-31) — Total Assets: 3414560000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Capitalization: 1850493000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Debt: 928729000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 1400818000.00
CURA.TO income_statement (annual, 2022-12-31) — Total Expenses: 1210432000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 2013742000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 2762135000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 1516874000.00
CURA.TO income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 64988000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Total Tax Payable: 159254000.00
CURA.TO income_statement (annual, 2022-12-31) — Total Unusual Items: -61006000.00
CURA.TO income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -61006000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Tradeand Other Payables Non Current: 94516000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Treasury Stock: 5208000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Work In Process: 102050000.00
CURA.TO balance_sheet (annual, 2022-12-31) — Working Capital: 155557000.00
CURA.TO income_statement (annual, 2023-12-31) — +Operating Expense: 571566000.00
CURA.TO income_statement (annual, 2023-12-31) — +Total Revenue: 1346632000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Accounts Payable: 79319000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Accounts Receivable: 59998000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -264568000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 2204318000.00
CURA.TO cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 67076000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Assets Held For Sale Current: 17795000.00
CURA.TO income_statement (annual, 2023-12-31) — Basic Average Shares: 241374964.00
CURA.TO income_statement (annual, 2023-12-31) — Basic EPS: -1.17
CURA.TO cash_flow (annual, 2023-12-31) — Beginning Cash Position: 163177000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 514777000.00
CURA.TO cash_flow (annual, 2023-12-31) — Capital Expenditure: -70303000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 295780000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Capital Stock: 0.00
CURA.TO balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 83218000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 83218000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -66994000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -80953000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 91244000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash From Discontinued Financing Activities: -23000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash From Discontinued Investing Activities: 2266000.00
CURA.TO cash_flow (annual, 2023-12-31) — Cash From Discontinued Operating Activities: -15983000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Account Payable: 2230000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Accrued Expense: -13957000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Income Tax Payable: 47986000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Inventory: 9851000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Other Current Assets: 8505000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Other Current Liabilities: -16536000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Payable: 50216000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 36259000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Prepaid Assets: -4048000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Receivables: 110000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Tax Payable: 47986000.00
CURA.TO cash_flow (annual, 2023-12-31) — Change In Working Capital: 34141000.00
CURA.TO cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -12221000.00
CURA.TO cash_flow (annual, 2023-12-31) — Changes In Cash: -70443000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Common Stock: 0.00
CURA.TO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 1050642000.00
CURA.TO cash_flow (annual, 2023-12-31) — Common Stock Issuance: 11497000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Construction In Progress: 43704000.00
CURA.TO income_statement (annual, 2023-12-31) — Cost Of Revenue: 732183000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 79490000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Assets: 418603000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 25421000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Debt: 39478000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 64899000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Deferred Liabilities: 23208000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Deferred Revenue: 866000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Current Liabilities: 494034000.00
CURA.TO cash_flow (annual, 2023-12-31) — Deferred Income Tax: -29900000.00
CURA.TO cash_flow (annual, 2023-12-31) — Deferred Tax: -29900000.00
CURA.TO cash_flow (annual, 2023-12-31) — Depreciation: 211914000.00
CURA.TO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 211914000.00
CURA.TO income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 136783000.00
CURA.TO cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 211914000.00
CURA.TO income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 136783000.00
CURA.TO income_statement (annual, 2023-12-31) — Diluted Average Shares: 241374964.00
CURA.TO income_statement (annual, 2023-12-31) — Diluted EPS: -1.17
CURA.TO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -281197000.00
CURA.TO cash_flow (annual, 2023-12-31) — Dividends Received Cfi: 0.00
CURA.TO income_statement (annual, 2023-12-31) — EBIT: -23984000.00
CURA.TO income_statement (annual, 2023-12-31) — EBITDA: 187930000.00
CURA.TO income_statement (annual, 2023-12-31) — Earnings From Equity Interest Net Of Tax: -22746000.00
CURA.TO cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -916000.00
CURA.TO cash_flow (annual, 2023-12-31) — End Cash Position: 91818000.00
CURA.TO cash_flow (annual, 2023-12-31) — Financing Cash Flow: -67017000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Finished Goods: 90807000.00
CURA.TO cash_flow (annual, 2023-12-31) — Free Cash Flow: 4958000.00
CURA.TO cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: -2073000.00
CURA.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: -8541000.00
CURA.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 2073000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -11875000.00
CURA.TO income_statement (annual, 2023-12-31) — General And Administrative Expense: 392791000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Goodwill: 626628000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 1799073000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Gross Accounts Receivable: 59998000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Gross PPE: 1097833000.00
CURA.TO income_statement (annual, 2023-12-31) — Gross Profit: 614449000.00
CURA.TO income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 67076000.00
CURA.TO cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 100011000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Income Tax Payable: 198056000.00
CURA.TO income_statement (annual, 2023-12-31) — Insurance And Claims: 9066000.00
CURA.TO income_statement (annual, 2023-12-31) — Interest Expense: 100382000.00
CURA.TO income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 100382000.00
CURA.TO income_statement (annual, 2023-12-31) — Interest Income: 23000.00
CURA.TO income_statement (annual, 2023-12-31) — Interest Income Non Operating: 23000.00
CURA.TO cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 97936000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Interest Payable: 6330000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Inventory: 215913000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Invested Capital: 1638409000.00
CURA.TO cash_flow (annual, 2023-12-31) — Investing Cash Flow: -78687000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Investments And Advances: 15048000.00
CURA.TO cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 11497000.00
CURA.TO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 8612000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Land And Improvements: 8026000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 270359000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Long Term Debt: 548289000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 818648000.00
CURA.TO cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 8612000.00
CURA.TO cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -59995000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 188959000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Minority Interest: 120650000.00
CURA.TO income_statement (annual, 2023-12-31) — Minority Interests: 9140000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: -3630000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: 11497000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Net Debt: 504549000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: 1617000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income: -281197000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -281197000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -238955000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income Discontinuous Operations: -51382000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -281197000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -229815000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -238955000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -290337000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -4857000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Interest Income: -100359000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: 0.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -51383000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -51383000.00
CURA.TO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -100359000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Other Financing Charges: -27156000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -7020000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Net PPE: 833265000.00
CURA.TO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -65446000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: -748431000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Accounts Receivable: 30168000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 419000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 318495000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 419000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 297185000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Non Current Note Receivables: 0.00
CURA.TO income_statement (annual, 2023-12-31) — Normalized EBITDA: 259409000.00
CURA.TO income_statement (annual, 2023-12-31) — Normalized Income: -173346590.00
CURA.TO balance_sheet (annual, 2023-12-31) — Notes Receivable: 7020000.00
CURA.TO cash_flow (annual, 2023-12-31) — Operating Cash Flow: 75261000.00
CURA.TO cash_flow (annual, 2023-12-31) — Operating Gains Losses: 4403000.00
CURA.TO income_statement (annual, 2023-12-31) — Operating Income: 42883000.00
CURA.TO income_statement (annual, 2023-12-31) — Operating Revenue: 1346632000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 244575934.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Current Assets: 30397000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 39478000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 28107000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -11875000.00
CURA.TO income_statement (annual, 2023-12-31) — Other Gand A: 117011000.00
CURA.TO income_statement (annual, 2023-12-31) — Other Income Expense: -66890000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 1172445000.00
CURA.TO cash_flow (annual, 2023-12-31) — Other Non Cash Items: 20505000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 12571000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Non Current Liabilities: 214965000.00
CURA.TO income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 4589000.00
CURA.TO income_statement (annual, 2023-12-31) — Other Operating Expenses: 4212000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Payable: 7570000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Properties: 342367000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Other Receivables: 2379000.00
CURA.TO income_statement (annual, 2023-12-31) — Other Special Charges: -2065000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Payables: 298330000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 377820000.00
CURA.TO income_statement (annual, 2023-12-31) — Pretax Income: -124366000.00
CURA.TO cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 48000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Properties: 0.00
CURA.TO cash_flow (annual, 2023-12-31) — Provisionand Write Offof Assets: 2050000.00
CURA.TO cash_flow (annual, 2023-12-31) — Purchase Of Business: -3630000.00
CURA.TO cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -4857000.00
CURA.TO cash_flow (annual, 2023-12-31) — Purchase Of Investment: 0.00
CURA.TO cash_flow (annual, 2023-12-31) — Purchase Of PPE: -65446000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Raw Materials: 52118000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Receivables: 62680000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Receivables Adjustments Allowances: -6717000.00
CURA.TO income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 657052000.00
CURA.TO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 211914000.00
CURA.TO income_statement (annual, 2023-12-31) — Rent And Landing Fees: 48983000.00
CURA.TO income_statement (annual, 2023-12-31) — Rent Expense Supplemental: 48983000.00
CURA.TO cash_flow (annual, 2023-12-31) — Repayment Of Debt: -59995000.00
CURA.TO income_statement (annual, 2023-12-31) — Research And Development: 1421000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Restricted Cash: 8600000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: -1140751000.00
CURA.TO income_statement (annual, 2023-12-31) — Salaries And Wages: 226797000.00
CURA.TO cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
CURA.TO cash_flow (annual, 2023-12-31) — Sale Of PPE: 0.00
CURA.TO income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 41992000.00
CURA.TO income_statement (annual, 2023-12-31) — Selling General And Administration: 434783000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Share Issued: 244575934.00
CURA.TO income_statement (annual, 2023-12-31) — Special Income Charges: -73552000.00
CURA.TO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 20010000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 1050642000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: -748431000.00
CURA.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -15010590.00
CURA.TO income_statement (annual, 2023-12-31) — Tax Provision: 114589000.00
CURA.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.21
CURA.TO balance_sheet (annual, 2023-12-31) — Total Assets: 3096576000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 1598931000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Debt: 883547000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 1171292000.00
CURA.TO income_statement (annual, 2023-12-31) — Total Expenses: 1303749000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 1925284000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 2677973000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 1431250000.00
CURA.TO income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 42883000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Total Tax Payable: 211441000.00
CURA.TO income_statement (annual, 2023-12-31) — Total Unusual Items: -71479000.00
CURA.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -71479000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Tradeand Other Payables Non Current: 79142000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Treasury Stock: 1050000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Work In Process: 72988000.00
CURA.TO balance_sheet (annual, 2023-12-31) — Working Capital: -75431000.00
CURA.TO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 247511784.00
CURA.TO income_statement (quarterly, 2024-09-30) — Basic EPS: -0.21
CURA.TO cash_flow (quarterly, 2024-09-30) — Change In Income Tax Payable: 4495000.00
CURA.TO cash_flow (quarterly, 2024-09-30) — Change In Tax Payable: 4495000.00
CURA.TO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 247511784.00
CURA.TO income_statement (quarterly, 2024-09-30) — Diluted EPS: -0.21
CURA.TO balance_sheet (quarterly, 2024-09-30) — Treasury Stock: 0.00
CURA.TO income_statement (quarterly, 2024-09-30) — Write Off: 642000.00
CURA.TO income_statement (annual, 2024-12-31) — +Operating Expense: 616034000.00
CURA.TO income_statement (annual, 2024-12-31) — +Total Revenue: 1334299000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 79129000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 63990000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -389731000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 2237468000.00
CURA.TO cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 54245000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Assets Held For Sale Current: 15653000.00
CURA.TO income_statement (annual, 2024-12-31) — Basic Average Shares: 246941699.00
CURA.TO income_statement (annual, 2024-12-31) — Basic EPS: -0.96
CURA.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 91818000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 499279000.00
CURA.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -97438000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 285203000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 0.00
CURA.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 93026000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 93026000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -54094000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -95459000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 169127000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash From Discontinued Financing Activities: -144000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash From Discontinued Investing Activities: 1629000.00
CURA.TO cash_flow (annual, 2024-12-31) — Cash From Discontinued Operating Activities: -5503000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Account Payable: -5634000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Accrued Expense: 118415000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Income Tax Payable: -174588000.00
CURA.TO cash_flow (quarterly, 2024-12-31) — Change In Income Tax Payable: 12732000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Inventory: 4308000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -883000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: -16359000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Payable: -5634000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 112781000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Prepaid Assets: 3311000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Receivables: 2335000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Tax Payable: -174588000.00
CURA.TO cash_flow (quarterly, 2024-12-31) — Change In Tax Payable: 12732000.00
CURA.TO cash_flow (annual, 2024-12-31) — Change In Working Capital: 105493000.00
CURA.TO cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -7791000.00
CURA.TO cash_flow (annual, 2024-12-31) — Changes In Cash: 15556000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Common Stock: 0.00
CURA.TO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 861214000.00
CURA.TO cash_flow (annual, 2024-12-31) — Common Stock Issuance: 0.00
CURA.TO balance_sheet (annual, 2024-12-31) — Construction In Progress: 67579000.00
CURA.TO income_statement (annual, 2024-12-31) — Cost Of Revenue: 693522000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 79295000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Assets: 434365000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 28328000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Debt: 101723000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 130051000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Deferred Liabilities: 35435000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Deferred Revenue: 2367000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Current Liabilities: 387925000.00
CURA.TO cash_flow (annual, 2024-12-31) — Deferred Income Tax: -54491000.00
CURA.TO cash_flow (annual, 2024-12-31) — Deferred Tax: -54491000.00
CURA.TO cash_flow (annual, 2024-12-31) — Depreciation: 248017000.00
CURA.TO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 248017000.00
CURA.TO income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 171804000.00
CURA.TO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 248017000.00
CURA.TO income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 171804000.00
CURA.TO income_statement (annual, 2024-12-31) — Diluted Average Shares: 249812221.00
CURA.TO income_statement (annual, 2024-12-31) — Diluted EPS: -0.96
CURA.TO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -238169000.00
CURA.TO cash_flow (annual, 2024-12-31) — Dividends Received Cfi: 0.00
CURA.TO income_statement (annual, 2024-12-31) — EBIT: -12742000.00
CURA.TO income_statement (annual, 2024-12-31) — EBITDA: 235275000.00
CURA.TO income_statement (annual, 2024-12-31) — Earnings From Equity Interest Net Of Tax: -22746000.00
CURA.TO cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -148000.00
CURA.TO cash_flow (annual, 2024-12-31) — End Cash Position: 107226000.00
CURA.TO cash_flow (annual, 2024-12-31) — Financing Cash Flow: -54238000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Finished Goods: 97945000.00
CURA.TO cash_flow (annual, 2024-12-31) — Free Cash Flow: 66186000.00
CURA.TO cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -6624000.00
CURA.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 4624000.00
CURA.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 5007000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -20080000.00
CURA.TO income_statement (annual, 2024-12-31) — General And Administrative Expense: 391522000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Goodwill: 628884000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 1714281000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 63990000.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Gross Accounts Receivable: 63990000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Gross PPE: 1153332000.00
CURA.TO income_statement (annual, 2024-12-31) — Gross Profit: 640777000.00
CURA.TO income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 54245000.00
CURA.TO cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 16486000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Income Tax Payable: 23414000.00
CURA.TO income_statement (annual, 2024-12-31) — Insurance And Claims: 9066000.00
CURA.TO income_statement (annual, 2024-12-31) — Interest Expense: 100616000.00
CURA.TO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 100616000.00
CURA.TO income_statement (annual, 2024-12-31) — Interest Income: 776000.00
CURA.TO income_statement (annual, 2024-12-31) — Interest Income Non Operating: 776000.00
CURA.TO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 96364000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Interest Payable: 10791000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Inventory: 216937000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Invested Capital: 1429834000.00
CURA.TO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -93830000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Investments And Advances: 1713000.00
CURA.TO cash_flow (annual, 2024-12-31) — Issuance Of Capital Stock: 0.00
CURA.TO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 22017000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Land And Improvements: 7616000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 256875000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Long Term Debt: 466897000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 723772000.00
CURA.TO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 22017000.00
CURA.TO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -64561000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 1713000.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Long Term Equity Investment: 1713000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 228886000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Minority Interest: 132179000.00
CURA.TO income_statement (annual, 2024-12-31) — Minority Interests: 6584000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 3788000.00
CURA.TO cash_flow (quarterly, 2024-12-31) — Net Business Purchase And Sale: 4729000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: 0.00
CURA.TO balance_sheet (annual, 2024-12-31) — Net Debt: 475594000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: 1617000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income: -238169000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -238169000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -234355000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income Discontinuous Operations: -10398000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -238169000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -227771000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -211609000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -244753000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -5000000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Interest Income: -99840000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -708000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -42544000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -42544000.00
CURA.TO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -99840000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -11706000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: -2483000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Net PPE: 763601000.00
CURA.TO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -91056000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: -853067000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Accounts Receivable: 20041000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 401000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 246773000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 401000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 244773000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Note Receivables: 2037000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 10322000.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Non Current Prepaid Assets: 10322000.00
CURA.TO income_statement (annual, 2024-12-31) — Normalized EBITDA: 279632000.00
CURA.TO income_statement (annual, 2024-12-31) — Normalized Income: -192728970.00
CURA.TO balance_sheet (annual, 2024-12-31) — Notes Receivable: 451000.00
CURA.TO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 163624000.00
CURA.TO cash_flow (annual, 2024-12-31) — Operating Gains Losses: -9888000.00
CURA.TO income_statement (annual, 2024-12-31) — Operating Income: 24743000.00
CURA.TO income_statement (annual, 2024-12-31) — Operating Revenue: 1334299000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 250019640.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Current Assets: 28067000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 101723000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 20075000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -20080000.00
CURA.TO income_statement (annual, 2024-12-31) — Other Gand A: 74838000.00
CURA.TO income_statement (annual, 2024-12-31) — Other Income Expense: -38261000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 1085397000.00
CURA.TO cash_flow (annual, 2024-12-31) — Other Non Cash Items: 12011000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 2947000.00
CURA.TO balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: 2947000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 205657000.00
CURA.TO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 6096000.00
CURA.TO income_statement (annual, 2024-12-31) — Other Operating Expenses: 4212000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Payable: 5821000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Properties: 349972000.00
CURA.TO balance_sheet (annual, 2024-12-31) — Other Receivables: 4763000.00
CURA.TO income_statement (annual, 2024-12-31) — Other Special Charges: -257000.00
CURA.TO income_statement (quarterly, 2024-12-31) — Other Special Charges: -12000.00